不同肾素-血管紧张素系统抑制剂对糖尿病肾病主要肾脏结局的疗效比较:网络荟萃分析
结果显示,目标剂量的ACEI/ARB在终末期肾病、血肌酐翻倍及蛋白尿变化上无显著差异,抗蛋白尿效应相似;结论受限于剂量等效性缺乏及部分结局数据稀少。
要点
- 目标剂量的ACEI与ARB在终末期肾病和血肌酐翻倍上无显著差异。
- 各类ACEI/ARB对蛋白尿的降低、进展或缓解效果相似。
- 证据受限于缺乏剂量等效性和部分结局数据不足。
核心结论
- 基于现有证据,目标剂量的个体ACEI与ARB对主要肾脏结局的影响无或几乎没有差异。
研究设计与样本
- 采用贝叶斯框架网络荟萃分析,随机效应模型,检索PubMed、Embase、Scopus、Cochrane CENTRAL和ClinicalTrials.gov。
- 比较ACEI或ARB单药治疗与其他常规降压药或安慰剂的疗效。
主要发现
- 个体ACEI和ARB在目标剂量下对终末期肾病和血肌酐翻倍无显著差异。
- 它们对蛋白尿/蛋白尿的降低、进展至大量白蛋白尿或缓解至正常白蛋白尿的效果相似。
- 将三个蛋白尿/蛋白尿结局合并为单一终点时,多数ACEI/ARB一致显示有利的抗蛋白尿效应,成为优越治疗的可能性差异很小。
- 主要结局在meta回归和敏感性分析中未见实质性改变。
关键数值与推荐
- 主要结局为终末期肾病和蛋白尿/蛋白尿(包括变化、进展至大量白蛋白尿、缓解至正常白蛋白尿)。
- 次要结局为血清肌酐翻倍。
- 还评估了高钾血症、咳嗽和血管性水肿/水肿。
临床怎么用
- 临床选择ACEI或ARB时,可基于患者耐受性和成本等因素,疗效差异不显著。
- 目标剂量的ACEI/ARB均能有效降低蛋白尿,应优先使用至目标剂量。
- 需监测高钾血症、咳嗽和血管性水肿/水肿等不良反应。
局限性
- 缺乏剂量等效性数据。
- 部分结局数据稀少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) are two drug classes with well-documented renal protective effects. However, whether there is any difference among individual drugs remains unknown. In this study, we aimed to compare the efficacy of individual ACEIs/ARBs on major renal outcomes in adults with diabetic kidney disease (DKD). METHODS: We conducted a Bayesian-framework network meta-analysis with a random effects model. We searched PubMed, Embase, Scopus, the Cochrane Central Register of Controlled Trials and ClinicalTrials.gov for clinical trials of ACEIs or ARBs as monotherapy compared with other conventional antihypertensive drugs or placebo. Primary outcomes were end-stage renal disease (ESRD) and albuminuria/proteinuria (including change in albuminuria/proteinuria, progression to macroalbuminuria and remission to normoalbuminuria). Secondary outcome was doubling of serum creatinine levels. We also assessed for hyperkalemia, cough and angioedema/edema. International prospective register of systematic reviews (PROSPERO) registration CRD42016036997. RESULTS: A total of 100 studies with data for 22 365 DKD patients, the majority of whom had type 2 diabetes, were included. Individual ACEIs and ARBs at goal doses showed no significant differences in ESRD and doubling of serum creatinine levels. They also shared similar effects on albuminuria/proteinuria reduction and progression or remission of albuminuria. When combining three outcomes of albuminuria/proteinuria as a single endpoint, most ACEIs/ARBs consistently showed favorable antiproteinuric effect, with little difference in the possibility of being the superior treatment for improving albuminuria/proteinuria. Primary outcomes did not change substantially in meta-regressions and sensitivity analyses. Findings were limited by lack of dose equivalence and paucity of data for some outcomes. CONCLUSIONS: Based on the available evidence, individual ACEIs and ARBs at goal doses appeared to have no or little differences in their effect on major renal outcomes.
引用
- Cai J, Huang X, Zheng Z, et al. Comparative efficacy of individual renin-angiotensin system inhibitors on major renal outcomes in diabetic kidney disease: a network meta-analysis. Nephrol Dial Transplant. 2018. PMID: 29579289. doi:10.1093/ndt/gfy001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。